Novo Nordisk A/S has repurchased 25,919,179 B shares worth a total of DKK 7.16 billion as part of its ongoing share repurchase programme, according to a Form 6-K filing dated July 27, 2026. The company said the purchases were made at an average price of DKK 276.33 per share as of July 24.
The buyback forms part of a broader programme under which Novo Nordisk plans to repurchase B shares for up to DKK 15 billion over a 12-month period beginning February 4, 2026. A separate sub-programme launched on May 6 allows the company to purchase up to DKK 11.2 billion worth of shares through February 1, 2027.
Latest Share Purchases
Between July 20 and July 24, Novo Nordisk repurchased a combined 960,000 B shares. The transactions were conducted at average prices ranging from DKK 313.46 to DKK 329.69 per share, with the total value of these purchases reaching approximately DKK 309.2 million.
The company has accumulated 11.16 million shares under the May 6 sub-programme, representing a transaction value of approximately DKK 3.36 billion.
Treasury Shares Reach 1% of Share Capital
Following the latest transactions, Novo Nordisk holds 43,104,480 B shares as treasury shares. These shares represent approximately 1% of the company’s total share capital, which consists of 4.465 billion A and B shares, including treasury stock.
Share buybacks can reduce the number of shares available in the market and potentially support per-share financial metrics. They may also signal that management believes the company has sufficient financial flexibility to return capital to shareholders while continuing to invest in its operations.
Investor Focus
The latest buyback update comes as investors continue to monitor Novo Nordisk’s performance in the highly competitive diabetes and obesity-drug markets. The company’s ADRs trade on the New York Stock Exchange under the ticker NVO, while its B shares are listed on Nasdaq Copenhagen.
The key question for investors is whether Novo Nordisk’s continued capital returns can help support shareholder value while the company navigates competition, changing market expectations and the need to maintain investment in its future drug pipeline.
